News and Press Releases
Ellipses In-Licences First in Class Novel Immuno-Oncology Agent with Potential as a Next Generation Checkpoint Inhibitor
11 February 2025 -- London, UK -- Ellipses Pharma Limited, a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced...
Category: BioManufacturing, Drug Discovery, Other, Pharmaceutical
Posted: February 11, 2025
Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER-ILD, in progressive pulmonary fibrosis
Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52 versus...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 10, 2025
Venus Remedies gets Marketing Authorization for anticoagulant ‘Enoxaparin’ from Indonesia
Latest approvals from Indonesia, Southeast Asia’s largest pharma market, to help strengthen company’s regional and global aspirations 10 February 2025 -- Panchkula, India -- Venus Remedies Limited, a leading Indian exporter...
Category: Drug Delivery, Other, Pharmaceutical
Posted: February 10, 2025
51-52, Industrial Area Phase-1, Panchkula, Haryana, 134113
ENA Respiratory Receives US$5m Investment from Flu Lab to Support Clinical Development of Novel Intranasal Antiviral Host Defence Immune Enhancer, INNA-051
10 February 2025 -- Melbourne, Australia -- ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence immune enhancers to minimize the impact of viral respiratory infections, announces today it...
Category: Biotechnology, Drug Delivery, Drug Discovery, Other, Pharmaceutical
Posted: February 10, 2025
Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds
7 February 2025 -- Bagsværd, Denmark -- Novo Nordisk today announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia A with...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 7, 2025
BioTrinity 2025, 1-2 April, Convene, 133 Houndsditch, London
About BioTrinity: BioTrinity, now in its 19th year, is OBN's flagship two-day conference for the life sciences industry, designed to catalyse growth for all who attend. The two-day conference programme for 2025...
Category: BioManufacturing
Posted: February 6, 2025
Kite Presents New Data on Patient Outcomes with CAR T-Cell Therapy at the 7th European CAR T-Cell Meeting, 6-8 February, Strasbourg, France
6 February 2025 -- Stockley Park, UK -- Kite, a Gilead Company, will share four posters that add to the growing body of evidence to support the clinical use of...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 6, 2025
Novel Findings Using the Parsortix System Demonstrating Role of CTC:B Cell Clusters in Driving Cancer Progression
Findings may enable the development of novel drugs to target B cell and CTC cluster interactions to suppress cancer metastasis This pivotal work is likely to stimulate further interest in...
Category: Drug Discovery, Other, Pharmaceutical
Posted: February 6, 2025
BioMed X Institute and Merck Successfully Complete Extrachromosomal DNA in Cancer Research Project
The research of BioMed X team EDC - Extrachromosomal DNA in Cancer - has uncovered critical insights into the mechanisms driving extrachromosomal DNA (ecDNA) formation and maintenance, offering potential avenues for...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 6, 2025
ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded
February 04, 2025 – Berlin, Germany – Biotech Newswire / -- ProBioGen has launched its new, redesigned website to provide biotech and biopharma professionals with clear access to its expanded...
Category: Biotechnology
Posted: February 5, 2025
Recipharm expands aseptic filling capabilities for process development, pilot scale and clinical supply
GMP aseptic filling under isolator conditions, for process development, pilot scale and clinical supply projects Supports various containers, including pre-filled syringes and liquid vials Complements existing sterile development and commercial...
Category: Drug Delivery, Manufacturing and Packing
Posted: February 5, 2025
CHMP recommends subcutaneous RYBREVANT®▼ (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer
Data from the Phase 3 PALOMA-3 study showed non-inferiority to intravenous administration meeting both co-primary pharmacokinetic (PK) endpoints, as well as a five-fold reduction in infusion-related reactions and fewer venous...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 3, 2025
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
CARBOGEN AMCIS Announces Leadership Transition
3 February 2025 – Bubendorf, Switzerland –Switzerland-based CARBOGEN AMCIS, a leading pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, has announced the departure of its current CEO, Pascal...
Category:
Posted: February 3, 2025
Fondazione Telethon Submits EU Marketing Authorisation Application for Etuvetidigene Autotemcel Gene Therapy for the Treatment of Wiskott-Aldrich Syndrome
3 February 2025 -- Milan, Italy -- Fondazione Telethon, an Italian biomedical charity focused on rare genetic diseases, announced that it has submitted the Marketing Authorization Application (MAA) for the...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other
Posted: February 3, 2025
FlyPharma 2025 Amsterdam officially announced as contracts are signed with host sponsors
FlyPharma, the leading platform for the pharmaceutical logistics and supply chain industry, is thrilled to announce its ninth European conference, which will take place in Amsterdam from October 8-9, 2025....
Category:
Posted: February 3, 2025
